• Engage with insights and updates from 18+ leading speakers from companies at the forefront of Fc-mediated therapeutics including, Argenx and AbbVie

• Explore the latest breakthroughs and advancements, including novel antibody formats and innovative Fc-engineering strategies for enhanced efficacy and affinity

• Discover cutting-edge research and innovative solutions for optimizing antibody design, enhancing Fc functionality, and extending half-life

• Investigate the most up-to-date approaches for minimizing the risk of immunogenicity and off-target effects associated with Fc-based therapies, ensuring the development of safer and more tolerable treatments for patients

• Network and connect with 50+ influential experts in immunology and drug development to exchange knowledge, establish impactful collaborations, and expand your network within this rapidly evolving field